CDKN2A and adenocarcinoma: However, a CDKN2A deletion in mutant KRAS-expressing mice prevented the progression to senescence and led to invasive and metastasizing adenocarcinomas with morphological and molecular features similar to KRAS-mutated adenocarcinomas.